Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 107

Similar articles for PubMed (Select 14664498)

1.

IARC downgrading of DEHP.

Brody C, DiGangi J, Easthope T, Rossi M, Schettler T.

Int J Occup Environ Health. 2003 Oct-Dec;9(4):399-400. No abstract available.

PMID:
14664498
2.

IARC and the DEHP quagmire.

Huff J.

Int J Occup Environ Health. 2003 Oct-Dec;9(4):402-4. No abstract available.

PMID:
14664499
3.

The IARC evaluation of di(2-ethylhexyl)phthalate (DEHP): a flawed decision based on an untested hypothesis.

Melnick RL.

Int J Occup Environ Health. 2002 Jul-Sep;8(3):284-6. No abstract available.

PMID:
12358086
4.

The IARC evaluation of DEHP excludes key papers demonstrating carcinogenic effects.

Melnick RL, Brody C, DiGangi J, Huff J.

Int J Occup Environ Health. 2003 Oct-Dec;9(4):400-2. No abstract available.

PMID:
15688552
5.

Comment from the union participant in the IARC Working Group that downgraded DEHP.

Mirer FE.

Int J Occup Environ Health. 2003 Jan-Mar;9(1):85-7. No abstract available.

PMID:
12749640
6.

Suppression of crucial information in the IARC evaluation of DEHP.

Melnick RL.

Int J Occup Environ Health. 2003 Jan-Mar;9(1):84-5; discussion 89. No abstract available.

PMID:
12749639
7.

IARC monographs, industry influence, and upgrading, downgrading, and under-grading chemicals: a personal point of view. International Agency for Research on Cancer.

Huff J.

Int J Occup Environ Health. 2002 Jul-Sep;8(3):249-70. Erratum in: Int J Occup Environ Health. 2003 Jan-Mar;9(1):84.

PMID:
12358081
8.

Lead IARC towards compliance with WHO/IARC Declaration of Interests (DOI) policy.

Sass J.

Int J Occup Environ Health. 2002 Jul-Sep;8(3):277-8. No abstract available.

PMID:
12358083
9.

The safety of many significant chemicals to which humans may be exposed.

Jacobson MF, Clapp R, Legator M, Lijinsky W, Reuber MD.

Int J Occup Environ Health. 2002 Jul-Sep;8(3):279-80. No abstract available.

PMID:
12358084
10.
11.

A cancer risk assessment of di(2-ethylhexyl)phthalate: application of the new U.S. EPA Risk Assessment Guidelines.

Doull J, Cattley R, Elcombe C, Lake BG, Swenberg J, Wilkinson C, Williams G, van Gemert M.

Regul Toxicol Pharmacol. 1999 Jun;29(3):327-57. Review.

PMID:
10388618
12.

Integrity of the conduct of the IARC monographs program.

Kleihues P.

Int J Occup Environ Health. 2003 Jan-Mar;9(1):78-9; author reply 82. No abstract available.

PMID:
12749635
13.

Di(2-ethylhexyl) phthalate.

[No authors listed]

IARC Monogr Eval Carcinog Risks Hum. 2000;77:41-148. Review. No abstract available.

PMID:
11100399
14.
15.

Di(2-ethylhexyl) phthalate.

National Toxicology Program.

Rep Carcinog. 2002;10:125-7. No abstract available. Update in: Rep Carcinog. 2004;11:III123-4.

16.

Industry influences IARC carcinogenesis evaluations.

Huff J.

Int J Occup Environ Health. 2003 Jan-Mar;9(1):83-4. No abstract available.

PMID:
16304740
17.

Di(2-ethylhexyl) phthalate.

National Toxicology Program.

Rep Carcinog. 2011;12:156-9. No abstract available.

PMID:
21852822
18.

DI-2-ethylhexyl phthalate and endocrine disruption: a review.

Latini G, Verrotti A, De Felice C.

Curr Drug Targets Immune Endocr Metabol Disord. 2004 Mar;4(1):37-40. Review.

PMID:
15032624
19.

Comments on some aspects of the present IARC practice.

Hansen ES.

Int J Occup Environ Health. 2003 Oct-Dec;9(4):396. No abstract available.

PMID:
14664496
20.

False positives in cancer epidemiology.

McLaughlin JK, Tarone RE.

Cancer Epidemiol Biomarkers Prev. 2013 Jan;22(1):11-5. doi: 10.1158/1055-9965.EPI-12-0995. Epub 2012 Nov 1. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk